Barclays raised the firm’s price target on Illumina to $100 from $85 and keeps an Underweight rating on the shares. The analyst says Q1 is shaping up to be a rather inconsequential “do nothing” quarter for the life science tools and diagnostics space. The firm does not expect to get a lot of data one way or the other on many of the bull/bear debates. It believes investors continue to favor bioprocessing names broadly over instrument-focused companies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina Announces Executive Shift and New CFO Appointment
- Early notable gainers among liquid option names on March 21st
- EU opinion could mean Illumina no longer required to fund GRAIL, says Guggenheim
- Illumina downgraded to Mixed from Positive view at OTR Global
- Early notable gainers among liquid option names on March 19th
